&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-01-13, 13:00

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-15, 13:00

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
Jannie Boothby

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-22, 18:00

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Conrad Southern

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-08, 18:00

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Genie Cordner

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-05-22, 12:00

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-30, 12:00

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-22, 12:00

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Bradley Crotty

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-01-31, 13:00

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-01-22, 13:00

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Popular Posts